Douglas Baum - Qsam Biosciences CEO CoFounder
| QSAMDelisted Stock | USD 4.49 0.05 1.13% |
Insider
Douglas Baum is CEO CoFounder of Qsam Biosciences
| Age | 56 |
| Phone | 512 343 4558 |
| Web | https://qsambio.com |
Qsam Biosciences Management Efficiency
The company has return on total asset (ROA) of (2.3809) % which means that it has lost $2.3809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (33.7707) %, meaning that it created substantial loss on money invested by shareholders. Qsam Biosciences' management efficiency ratios could be used to measure how well Qsam Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Qsam Biosciences currently holds 7.5 K in liabilities with Debt to Equity (D/E) ratio of 2.08, implying the company greatly relies on financing operations through barrowing. Qsam Biosciences has a current ratio of 0.23, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Qsam Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Qsam Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Qsam Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Qsam to invest in growth at high rates of return. When we think about Qsam Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dominic Cundari | DiaMedica Therapeutics | 74 | |
| Iraj Ali | Achilles Therapeutics PLC | 50 | |
| Robert Coutts | Achilles Therapeutics PLC | 41 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Samuel Berry | Fortress Biotech Pref | N/A | |
| Shachar CPA | Enlivex Therapeutics | 48 | |
| Pr Bayley | Oxford Nanopore Technologies | N/A | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Peter MBA | Marker Therapeutics | 52 | |
| Sara Le | Oxford Nanopore Technologies | N/A | |
| Gustavo Scaffa | ImmuCell | N/A | |
| Robert Bazemore | Nuvation Bio | 53 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| William Annett | Lineage Cell Therapeutics | 70 | |
| Jill Howe | Lineage Cell Therapeutics | 49 | |
| Pr MD | Enlivex Therapeutics | 68 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Stacy Markel | Nuvation Bio | 60 | |
| Richard Compton | Oxford Nanopore Technologies | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -33.77 | |||
| Return On Asset | -2.38 |
Qsam Biosciences Leadership Team
Elected by the shareholders, the Qsam Biosciences' board of directors comprises two types of representatives: Qsam Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qsam. The board's role is to monitor Qsam Biosciences' management team and ensure that shareholders' interests are well served. Qsam Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qsam Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam CPA, Chief Officer | ||
| Dr MA, CoFounder Chairman | ||
| Namrata Chand, Vice Operations | ||
| Douglas Baum, CEO CoFounder | ||
| Christopher Nelson, General Development |
Qsam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Qsam Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -33.77 | |||
| Return On Asset | -2.38 | |||
| Current Valuation | 36.03 M | |||
| Shares Outstanding | 4.45 M | |||
| Shares Owned By Insiders | 52.36 % | |||
| Price To Book | 201.64 X | |||
| Price To Sales | 1.71 X | |||
| Gross Profit | 916.67 K | |||
| EBITDA | (3.94 M) | |||
| Net Income | (4.39 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Qsam Biosciences information on this page should be used as a complementary analysis to other Qsam Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Qsam OTC Stock
If you are still planning to invest in Qsam Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Qsam Biosciences' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |